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ARTICLE
Lysolipid receptor cross-talk regulates lymphatic
endothelial junctions in lymph nodes
Yu Hisano1, Mari Kono2*, Andreane Cartier1*, Eric Engelbrecht1, Kuniyuki Kano3, Kouki Kawakami3, Yanbao Xiong4, Wenji Piao4, Sylvain Galvani1,
Keisuke Yanagida1, Andrew Kuo1, Yuki Ono3, Satoru Ishida3, Junken Aoki3, Richard L. Proia2, Jonathan S. Bromberg4, Asuka Inoue3, and Timothy Hla1
Sphingosine 1-phosphate (S1P) and lysophosphatidic acid (LPA) activate G protein–coupled receptors (GPCRs) to regulate
biological processes. Using a genome-wide CRISPR/dCas9–based GPCR signaling screen, LPAR1 was identified as an inducer of
S1PR1/β-arrestin coupling while suppressing Gαi signaling. S1pr1 and Lpar1-positive lymphatic endothelial cells (LECs) of
lymph nodes exhibit constitutive S1PR1/β-arrestin signaling, which was suppressed by LPAR1 antagonism. Pharmacological
inhibition or genetic loss of function of Lpar1 reduced the frequency of punctate junctions at sinus-lining LECs. Ligand activation
of transfected LPAR1 in endothelial cells remodeled junctions from continuous to punctate structures and increased
transendothelial permeability. In addition, LPAR1 antagonism in mice increased lymph node retention of adoptively
transferred lymphocytes. These data suggest that cross-talk between LPAR1 and S1PR1 promotes the porous junctional
architecture of sinus-lining LECs, which enables efficient lymphocyte trafficking. Heterotypic inter-GPCR coupling may
regulate complex cellular phenotypes in physiological milieu containing many GPCR ligands.
Introduction
Membrane phospholipids are rapidly metabolized by lipases and
synthases to maintain the integrity of biological membranes
(Shimizu, 2009). Lysophospholipids, metabolic intermediates of
membrane phospholipids, have unique geometry and biophysi-
cal properties that facilitate membrane topology, vesicle bud-
ding, and fusion (Holthuis and Menon, 2014). However,
lysophospholipids evolved as extracellular lipid mediators in
vertebrates (Hla, 2005). The best characterized are sphingosine
1-phosphate (S1P) and lysophosphatidic acid (LPA), structurally
related lysophospholipids that were originally identified as ma-
jor regulators of cellular cytoskeletal dynamics (Blaho and Hla,
2011; Moolenaar and Hla, 2012; Mutoh et al., 2012). S1P is syn-
thesized largely in the intracellular environment and secreted
via specific transporters SPNS2 andMFSD2B (Hisano et al., 2011;
Proia and Hla, 2015; Vu et al., 2017; Kobayashi et al., 2018). Ex-
tracellular chaperone-bound S1P activates five G protein–
coupled receptors (GPCRs) in the endothelial differentiation gene
subfamily that are widely expressed (Proia and Hla, 2015). On
the other hand, LPA, which is synthesized in the extracellular
environment by autotaxin-mediated hydrolysis of lysophospha-
tidyl choline, activates six GPCRs in the endothelial differentia-
tion gene and purinergic subfamilies (Aikawa et al., 2015).
Both S1P and LPA were originally identified as bioactive lipid
mediators due to their ability tomodulate cytoskeletal dynamics,
neurite retraction, cell migration, cell proliferation, and intra-
cellular ion fluxes (Moolenaar and Hla, 2012). Such activity
depends on the ability of S1P and LPA to regulate Rho family
GTPases (Hall, 2012). After the discovery of the GPCRs for S1P
and LPA, genetic loss-of-function studies in mice have identified
their essential roles in embryonic development and physiologi-
cal processes of multiple organ systems (Chun et al., 2010). For
example, both lysophospholipids were shown to be critical for
early vascular development, since mice that lack autotaxin
(Enpp2) as well as sphingosine kinases (Sphk1 and Sphk2) were
embryonic lethal at early stages of gestation (Mizugishi et al.,
2005; Tanaka et al., 2006; van Meeteren et al., 2006). Similarly,
compound S1P and LPA receptor KOs also exhibit severe vas-
cular development defects (Kono et al., 2004; Sumida et al.,
2010). Similar studies have implicated the critical roles of S1P
and LPA signaling in neuronal and immune systems (Skoura and
Hla, 2009). A key question that is raised by such findings is
whether S1P and LPA are redundant in their biological functions.
Data available so far suggest that while some redundant func-
tions are mediated by both lysophospholipids, some unique
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functions do exist. For example, naive T cell egress from sec-
ondary lymphoid organs is largely dependent on S1P signaling
via lymphocyte S1PR1 (Cyster and Schwab, 2012), whereas both
S1P and LPA induce fibrotic responses in the lung (Shea and
Tager, 2012) and regulate cardiac development in zebrafish
(Nakanaga et al., 2014). Whether S1P and LPA signaling mech-
anisms regulate each other (i.e., cross-talk mechanisms) is
not known.
The S1PR1 receptor signals primarily via the Gi family of
heterotrimeric G proteins (Lee et al., 1999). However, its acti-
vity is antagonized by β-arrestin–mediated receptor down-
regulation, which involves GRK2-dependent phosphorylation,
β-arrestin binding, and dynamin-regulated endocytosis (Oo
et al., 2007, 2011; Arnon et al., 2011; Willinger et al., 2014). In
addition, direct binding to the membrane-bound C-type lectin
CD69 also induces receptor down-regulation (Shiow et al., 2006;
Bankovich et al., 2010). Further, extracellular presence of ApoM-
containing high density lipoprotein, which chaperones S1P,
permits sustained plasma membrane signaling without inducing
efficient endocytosis (Swendeman et al., 2017). We hypothesized
that novel factors modulate its signaling and residency in the
plasmamembrane tomediate its multiple biological functions. In
this report, we searched for novel regulators of S1PR1 coupling to
the β-arrestin pathway. Specifically, we used the TANGO sys-
tem, which uses tobacco etch virus (TEV) protease/β-arrestin
fusion protein and S1PR1-TEV site tetracycline transcriptional
activator as a readout (Barnea et al., 2008). Coupled with the
single guide RNA (sgRNA) library-directed, CRISPR/dCas9-in-
duced endogenous genes (Shalem et al., 2015), we screened for
novel modulators of S1PR1. Surprisingly, the top hit from this
unbiased, whole-genome screen was LPAR1. We validated this
interaction in a luciferase complementation system that quan-
tifies GPCR coupling to β-arrestin. Our results suggest that
LPAR1’s interaction with S1PR1 attenuates S1P signaling in en-
dothelial cells, modulates lymphatic sinus adherens junctions,
and provides a permissive niche for lymphocyte trafficking.
Results
Unbiased, genome-wide search for S1PR1 modulators
S1PR1 signaling can be readily monitored by the TANGO system,
which records ligand-activated β-arrestin coupling to the GPCR,
leading to nuclear fluorescent protein expression in vitro and
in vivo (Kono et al., 2014). Since the receptor/β-arrestin signal is
cumulative due to the stability of the nuclear fluorescent pro-
tein, we adapted this system to U2OS osteosarcoma cells that are
adaptable to high-throughput screening. Previous work has
shown that direct activators of S1PR1, such as CD69, regulate
receptor signaling and function (Shiow et al., 2006; Bankovich
et al., 2010). To search for other endogenous modulators of
S1PR1 signaling, we turned to the synergistic activationmediator
(SAM) system that uses CRISPR/dCas9-based, sgRNA-dependent
transcriptional activation of endogenous genes (Konermann
et al., 2015).
The SAM system turns on endogenous gene expression by
sgRNA-dependent recruitment of multiple transcriptional acti-
vators (VP64, p65, and HSF1) upstream of transcription start
sites via MS2 bacteriophage coat proteins and mutated,
nuclease-deficient dCas9. This screening system was validated
by the SAM sgRNA targeting SPNS2, an S1P transporter that
functions upstream of S1P receptors (Kawahara et al., 2009;
Hisano et al., 2012, 2013). The designed SPNS2 SAM sgRNA in-
duced an 180-fold increase in its mRNA expression and strongly
activated the S1PR1-TANGO signal (Fig. S1, A and B).
To carry out unbiased search for S1PR1-signaling modulators,
the SAM sgRNA library was introduced into the S1PR1-TANGO
system, inwhich β-arrestin2 coupling of S1PR1 can bemonitored
as nuclear expression of Venus fluorescent protein. Venus-
positive cells (S1PR1/β-arrestin2 signaling positive) were sor-
ted and expanded twice, and genomic DNAs were purified and
sequenced by Illumina next-generation sequencing (NGS; Fig. 1
A). Bioinformatic analysis indicated that some SAM sgRNA se-
quences are highly enriched in the Venus-positive cells after
sorting (Fig. 1 B), suggesting that target genes of these sgRNAs
encode proteins that enable S1PR1 coupling to β-arrestin. The
LPAR1 gene was identified as one of the top hits (Fig. 1 C). Top 10
candidates were examined individually by specific SAM sgRNAs
that were enriched after sorting Venus-positive cells. The SAM
sgRNA specific for LPAR1 induced its expression and turned on
Venus expression, thus confirming the results from the genome-
wide sgRNA screen that identified LPAR1 as a modulator of
S1PR1 coupling to β-arrestin (Fig. S1, C and D).
LPAR1 activation induces β-arrestin recruitment to S1PR1
To further investigate the mechanisms involved in the regu-
lation of S1PR1 signaling by LPAR1, we used the NanoBiT
system (Dixon et al., 2016). This system is based on the
structural complementation of NanoLuc luciferase and allows
one to monitor the protein–protein interactions in real time.
NanoLuc luciferase is split into a small subunit (SmBiT; 11
amino acids) and a large subunit (LgBiT; 18 kD) that are fused
with S1PR1 and β-arrestin1 with mutations in AP-2/clathrin-
binding motif (to reduce endocytosis), respectively (Fig. 2 A).
S1P dose-dependently stimulated β-arrestin1 recruitment to
S1PR1 in HEK293A cells transfected with S1PR1-SmBiT and
LgBiT-β-arrestin1. However, the S1P ligand–binding mutant,
S1PR1 (R120A), did not recruit β-arrestin upon treatment with
S1P (Fig. 2 B). LPA treatment did not induce β-arrestin1 re-
cruitment to S1PR1, consistent with the fact that LPA is not a
high-affinity ligand for S1PR1 (Lee et al., 1998a; Liu et al.,
1999). However, in cells coexpressing LPAR1 and S1PR1-
SmBiT, LPA treatment induced β-arrestin1 recruitment to
S1PR1 with a 50% effective concentration of ∼10−7 M, a
physiologically relevant concentration of LPA (Fig. 2 C).
The effect of LPA was completely blocked by Ki16425, an LPAR1
antagonist (Ohta et al., 2003), indicating that the β-arrestin1 cou-
pling of S1PR1 is dependent on LPAR1 activation by the ligand
(Fig. 2 D). W146, an S1PR1 antagonist, inhibited S1P-mediated
β-arrestin1 recruitment to S1PR1 but failed to inhibit LPA/LPAR1–
mediated β-arrestin1 coupling of S1PR1 (Fig. 2, D and E), suggesting
that S1PR1 activation with S1P is not necessary for the LPA/
LPAR1–mediated stimulation of S1PR1 coupling to β-arrestin1. Fur-
thermore, the S1PR1 ligand–binding mutant (R120A) behaved simi-
larly to wild-type S1PR1 by allowing LPAR1-induced β-arrestin1
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coupling (Fig. 2 F). Simultaneous administration of both LPA and S1P
induced an additive effect on S1PR1 coupling to β-arrestin (Fig. S2).
These experiments confirm that LPAR1 activation induced inter-
GPCR coupling of β-arrestin to S1PR1 independently of acti-
vated S1PR1-induced β-arrestin recruitment.
G proteins are not required for LPA/LPAR1–induced S1PR1/
β-arrestin coupling
LPAR1 couples to three families of G protein α subunits (Gαi,
Gα12/13, and Gαq/11), while S1PR1 is a Gαi-coupled receptor
(Fukushima et al., 1998; Lee et al., 1998b; Windh et al., 1999; Ishii
et al., 2000). To examine whether LPAR1-induced inter-GPCR
coupling of β-arrestin1 to S1PR1 requires heterotrimeric G pro-
teins, we used HEK293 cells lacking GNAS, GNAL, GNAQ, GNA11,
GNA12, GNA13, GNAI1, GNAI2, GNAI3, GNAO1, GNAZ, GNAT1, and
GNAT2 (fullΔGα) generated with CRISPR/Cas9 system (Fig. S3).
Even in the HEK293 fullΔGα cells, S1P activation of S1PR1 induced
β-arrestin1 coupling to a similar extent as wild-type cells, sug-
gesting that GPCR/β-arrestin1 coupling is G-protein independent
(Figs. 2 B and 3 A), a finding that was reported previously
(Grundmann et al., 2018). We observed that LPA stimulation of
LPAR1 induced S1PR1/β-arrestin1 coupling in the HEK293 fullΔGα
cells (Fig. 3 B), indicating that heterotrimeric G protein coupling is
not required for inter-GPCR β-arrestin coupling.
The LPAR1 C-terminal domain is necessary for the β-arrestin
coupling of S1PR1
β-Arrestin primarily interacts with the intracellular C-terminal
tail region of GPCRs, even though the third intracellular loop
may also be involved (Ranjan et al., 2017). The LPAR1ΔC mutant,
which lacks the C-terminal domain, did not recruit β-arrestin1 in
response to LPA (Fig. 4 A). In contrast, both LPAR1 and LPAR1ΔC
receptors couple to the heterotrimeric Gαi protein in an equiv-
alent manner, which was assessed as dissociation of heteromeric
G proteins using LgBiT-GNAI2/SmBiT-GNG (Fig. 4 B). However,
LPAR1ΔC mutant was unable to induce β-arrestin1 recruitment
to S1PR1 in response to LPA (Fig. 4 C), suggesting that initial
β-arrestin1 recruitment to LPAR1 is required for the LPA-
mediated inter-GPCR coupling of β-arrestin to S1PR1.
Transmembrane helix 4 of S1PR1 is important for the
β-arrestin coupling of S1PR1
We next examined the hypothesis that direct interactions
between S1PR1 and LPAR1 are needed for inter-GPCR
Figure 1. Unbiased whole genome-wide search for S1PR1 modulators. (A) Schematic of the S1PR1 modulator screening system. Four lentiviral vectors
were transduced into a U2OS cell line to enable gene activation by SAM and monitor S1PR1 activation by the TANGO system. The cells introduced with a SAM
sgRNA library were starved with 0.5% charcoal–treated FBS, and then the Venus-positive population was sorted, and NGS analysis was performed to identify
the enriched SAM sgRNA sequences. (B) Scatterplot showing enrichment of sgRNAs after sorting. Most sgRNAs are equally distributed in the presort sample
(closed gray circles), while after sorting, a small fraction of sgRNAs (2,770 out of 70,290 sgRNAs) were enriched (open blue circles). The y axis shows the
number of NGS reads of sgRNAs. (C) Identification of top candidate genes using the MAGeCK method (Li et al., 2014). The names of top 10 candidate genes are
indicated. TRE, tetracycline-responsive element; NLS, nuclear localization signal.
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β-arrestin coupling. The transmembrane helix 4 of S1PR1
was reported to interact directly with CD69, a trans-
membrane C-type lectin (Bankovich et al., 2010). The
S1PR1(TM4) mutant in which transmembrane helix 4 is re-
placed with that of S1PR3 decreased the association with
CD69, suggesting that it is the domain involved in inter-
molecular association with GPCR modulators. We therefore
examined the role of the transmembrane helix 4 of S1PR1 in
LPAR1-mediated inter-GPCR β-arrestin coupling to S1PR1.
S1PR1(TM4)-SmBiT can be expressed at same level as S1PR1-
SmBiT (Fig. S4 A) and recruits β-arrestin1 after S1P stimu-
lation (Fig. 4 D). However, the LPAR1-mediated β-arrestin1
coupling of S1PR1(TM4) was significantly attenuated (Fig. 4
E), indicating that the transmembrane helix 4 of S1PR1 is
important for the LPAR1-mediated β-arrestin1 coupling of
S1PR1.
LPAR1-induced inter-GPCR β-arrestin coupling attenuates
S1PR1/Gi signaling
In many GPCRs, β-arrestin recruitment is an initial trigger for
receptor internalization by facilitating the interaction with AP-2
and clathrin to recruit GPCRs to the endocytic machinery (Tian
et al., 2014). S1PR1 with N-terminal Flag tag was expressed in
HEK293A cells, and LPAR1 cell-surface receptor expression was
analyzed by flow cytometry. Surprisingly, Flag-S1PR1 surface
expression was not altered by LPA stimulation while S1P stim-
ulation induced Flag-S1PR1 internalization (Fig. 5 A). Immuno-
fluorescence analysis confirmed these conclusions (Fig. S4 B).
These results suggest that while LPAR1-induced inter-GPCR
β-arrestin coupling to S1PR1, this event in and of itself is not
sufficient to induce S1PR1 endocytosis.
Next, we examined whether LPAR1 activation modu-
lates the S1PR1 signal transduction. Coupling of S1PR1 to the
Figure 2. Activated LPAR1 induces S1PR1/β-arrestin coupling. (A) Schematic of NanoBiT system to measure S1PR1 and the β-arrestin1 interaction. SmBiT
and LgBiT were fused to the C-terminus of S1PR1 and the N-terminus of β-arrestin1, respectively. S1PR1 and β-arrestin1 coupling can be detected as lumi-
nescence signal emitted by complementation of SmBiT and LgBiT. (B) S1PR1-SmBiT or S1PR1(R120A)-SmBiT was transfected with LgBiT-β-arrestin1,
and luminescence was measured 15–20 min after S1P stimulation. (C) LPAR1 or empty vector was transfected with S1PR1-SmBiT and LgBiT-β-arrestin1, and
luminescence was measured 15–20 min after LPA stimulation. (D and E) Cells were incubated with 1 µM Ki16425 or W146 for 30 min before stimulation, and
luminescence was measured 15–20 min after LPA (D) or S1P (E) stimulation. (F) LPAR1 or empty vector was transfected with S1PR1(R120A)-SmBiT and LgBiT-
β-arrestin1, and luminescence was measured 15–20 min after LPA stimulation. Experiments were repeated (i.e., three to eight independent experiments), and
results are expressed as mean ± SD. βARR, β-arrestin; RLU, relative light units.
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heterotrimeric G protein pathway was assessed using LgBiT-
GNAO1/SmBiT-GNG and AUY954, an S1PR1 selective agonist
(Pan et al., 2006). AUY954 induced S1PR1-mediated heteromeric
G protein dissociation in a dose-dependent manner, which was
significantly suppressed by coexpression with LPAR1 (Fig. 5 B).
Other LPA receptors (LPAR2 and LPAR5) expressed at similar
levels as LPAR1 failed to suppress S1PR1-mediated Gαi protein
activation (Fig. 5, B and C). These results indicate that LPAR1
specifically induces inter-GPCR β-arrestin coupling to suppress
S1PR1 heterotrimeric Gαi protein signaling output without in-
ducing receptor endocytosis.
Endogenous LPAR1 stimulates S1PR1/β-arrestin coupling
in vivo at lymphatic sinuses
Next, to examine whether endogenously expressed LPAR1 in-
duces inter-GPCR β-arrestin coupling to S1PR1, we isolated MEF
cells from S1PR1 luciferase signaling mice, in which endogenous
S1PR1/β-arrestin2 coupling can be monitored via the firefly split
luciferase fragment complementation system (Kono et al., 2017).
As shown in Fig. 6 A, LPA induced S1PR1/β-arrestin2 coupling in
a dose-dependent manner that was blocked by Ki16425, indi-
cating that the activation of endogenously expressed LPAR1 in-
duces inter-GPCR β-arrestin coupling to S1PR1.
S1PR1 luciferase signaling mice were used to determine if
LPAR1-induced inter-GPCR β-arrestin coupling to S1PR1 occurs
in vivo. As previously observed, significant S1PR1 coupling to
β-arrestin is seen in several organs in normal mice under ho-
meostatic conditions (Kono et al., 2017). AM095, an orally
available LPAR1 selective antagonist with desirable in vivo
pharmacokinetic features (Swaney et al., 2011), completely
blocked LPA/LPAR1–mediated β-arrestin1 coupling of S1PR1
in vitro (Fig. 6 B). Administration of AM095 to S1PR1 luciferase
signaling mice significantly decreased bioluminescence signals
(Fig. 6, C–E). Detailed imaging of dissected mice showed that
S1PR1 coupling to β-arrestin in lung, spleen, and lymph nodes
was significantly attenuated by AM095 treatment (Fig. 6, F–H).
Since lymphatic endothelial cells (LECs) express both LPAR1
and S1PR1 (Heng et al., 2008), we further examined the in vivo
relevance of LPAR1-induced inter-GPCR β-arrestin coupling to
S1PR1 in murine lymph nodes under homeostatic conditions. For
this, we used the S1PR1-GFP signaling mouse, which records
cumulative S1PR1 coupling to β-arrestin while allowing high-
resolution imaging studies (Kono et al., 2014). Immunofluores-
cence and confocal microscopy of brachial lymph node sections
in adult mice showed strong S1PR1 coupling to β-arrestin in LECs
that make up the cortical, medullary, and subcapsular sinuses
(Fig. 7, A and B). As previously reported (Kono et al., 2014), high
endothelial venules (HEVs) also exhibit S1PR1 coupling to
β-arrestin (Fig. S5 A). When mice were treated with the LPAR1
inhibitor AM095 for 5 d, S1PR1 coupling to β-arrestin in sinus-
lining LECs of lymph nodes was suppressed (Fig. 7, B–D). These
data are consistent with quantitative imaging data using S1PR1
luciferase signaling mice shown above.
High-resolution images of cell–cell junctions in sinus-lining
LECs of lymph nodes is shown in Fig. 8 A. The junctional
structure is complex and contains both continuous and punctate
vascular endothelial (VE)–cadherin– and PECAM-1–positive
structures. We compared the junctional architecture of sinus-
lining LECs from lymph nodes (lumbar, popliteal, brachial, and
mesenteric) of vehicle- and AM095-treated mice. Both punc-
tate and continuous VE-cadherin–positive LEC junctions were
quantified by image analysis. As shown in Fig. 8 B, the frequency
of punctate junctions was decreased and continuous junctions
increased in LECs of AM095-treated mice. Similarly junctional
architectural change was seen in sinus-lining LECs of brachial
lymph nodes from Lpar1 KO mice (Fig. S5, B and C). Together,
these data suggest that signaling of LPAR1 suppresses the for-
mation of continuous junctions and thus enhances the sinus LEC
junctional porosity.
LPAR1 remodels the sinus-lining LEC junctional architecture
and lymphocyte retention in lymph nodes
To examine whether LPAR1 modulates S1PR1-dependent barrier
function in an in vitro model of endothelial cells, LPAR1 was
expressed in HUVECs using an inducible lentiviral system (Fig.
S5 D), and barrier function was quantified by measuring
transendothelial electrical resistance (Stolwijk et al., 2015). As
expected, the S1PR1 agonist AUY954 induced a sustained
Figure 3. LPAR1-mediated S1PR1/β-arrestin
coupling in G protein–deficient cells. LPAR1
or empty vector was transfected with S1PR1-
SmBiT and LgBiT-β-arrestin1 into HEK293
fullΔGα cells lacking all Gαs. (A and B) Lumi-
nescence was measured 15–20 min after S1P
(A) or LPA (B) stimulation. Experiments were
repeated (i.e., n = 3 independent experiments),
and results are expressed as mean ± SD. βARR,
β-arrestin; RLU, relative light units.
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increase in vascular barrier function (Fig. 9 A). LPA itself did not
influence barrier function in the presence or absence of AUY954
(Fig. 9 A). However, in HUVECs expressing LPAR1, LPA induced
a small and transient increase in barrier function (Fig. 9 C). In
sharp contrast, LPA inhibited the AUY954-induced vascular
barrier increase significantly (Fig. 9 C). This was completely
reversed by Ki16425, an antagonist of LPAR1 (Fig. 9, B and D),
suggesting that LPAR1 induces inter-GPCR β-arrestin coupling to
attenuate S1PR1-induced barrier function and thereby enhance
the porosity of the endothelial monolayer.
To determine the cellular changes induced by LPAR1 and
S1PR1 inter-GPCR β-arrestin coupling, we examined the status of
VE-cadherin, a major junctional protein. F-actin and phospho-
myosin light chain (p-MLC) were also examined to determine
the role of Rho-coupled actin/myosin architecture, which is
known to be downstream of LPAR1 (Knipe et al., 2015). As an-
ticipated, S1PR1 activation by AUY954 strongly induced junc-
tional VE-cadherin (Fig. 9, E and F). In S1PR1-activated HUVECs,
minimal intercellular gaps were observed and VE-cadherin ap-
peared as continuous, zipper-like structures at cell–cell borders
(Fig. 9 F). Cortical F-actin was induced, and p-MLC staining was
attenuated, suggesting an increase in Rac GTPase activity and a
decrease in Rho GTPase activity, respectively (Fig. 9, E and F).
LPA treatment strongly induced intercellular gaps that punctu-
ate continuous VE-cadherin staining, strong F-actin staining,
and stress fibers and a marked increase in p-MLC staining
(Fig. 9 G). In the presence of both LPA and AUY954, junctional
architecture was modulated to contain a hybrid of continuous
cell–cell border staining interspersedwith punctate VE-cadherin
localization at the termini of actin stress fibers (Fig. 9 H). p-MLC
Figure 4. The C-terminus of LPAR1 and TM4 of S1PR1 is important for LPAR1-induced inter-GPCR β-arrestin coupling. (A) LPAR1-SmBiT or LPAR1ΔC-
SmBiT was transfected with LgBiT-β-arrestin1, and luminescence was measured 15–20 min after LPA stimulation. (B) A G-protein dissociation assay was
performed by transfecting LgBiT-GNAI2, GNB1, and SmBiT-GNGT1 plasmids with LPAR1 or LPAR1ΔC. Luminescence was measured 6–9 min after LPA
stimulation. (C) LPAR1 or LPAR1ΔC was transfected with S1PR1-SmBiT and LgBiT-β-arrestin1, and luminescence was measured 15–20 min after LPA stim-
ulation. (D) S1PR1-SmBiT or S1PR1(TM4)-SmBiT was transfected with LgBiT-β-arrestin1, and luminescence was measured 15–20 min after S1P stimulation. (E)
LPAR1 or empty vector was transfected with S1PR1-SmBiT or S1PR1(TM4)-SmBiT and LgBiT-β-arrestin1, and luminescence was measured 15–20 min after LPA
stimulation. Experiments were repeated (i.e., three to five independent experiments), and the results are expressed as mean ± SD. P values were determined by
two-way ANOVA followed by Sidak’s multiple comparisons test comparing “S1PR1(TM4)-SmBiT + LPAR1” to “S1PR1-SmBiT + LPAR1”; *, P = 0.0018; **, P ≤
0.001. βARR, β-arrestin; RLU, relative light units.
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and F-actin at stress fibers were slightly attenuated (Fig. 9, G and
H). However, intercellular gaps were induced when compared
with S1PR1-activated HUVECs (Fig. 9, F and H). Quantification of
VE-cadherin–positive junctions is shown in Fig. 9, I and J. Total
VE-cadherin staining intensity was increased by AUY954
treatment, which was blocked by LPAR1 activation. Continuous
junctions (3–25 µm) were stimulated by AUY954, which acti-
vates S1PR1. In contrast, LPAR1 activation induced punctate
junctions while suppressing continuous junctions. Thus, LPAR1
activation, which induces inter-GPCR β-arrestin coupling to
S1PR1, helps form complex cell–cell adherens junction archi-
tecture and decreased vascular barrier function. Similar cellular
mechanisms may occur in lymphatic endothelial sinuses to
regulate junctional porosity.
Lymphatic sinus junctional porosity may permit efficient
lymphocyte egress from lymph nodes. We therefore examined
the retention of adoptively transferred lymphocytes when
LPAR1 is inhibited by AM095. As shown in Fig. 10 A, intrave-
nously injected lymphocytes accumulated more in lymph nodes,
but not in spleen, when LPAR1 is inhibited. Lymph node sections
showed that adoptively transferred lymphocytes accumulated in
T cell–rich areas of lymph nodes (Fig. 10 B), suggesting that
lymph node retention is enhanced when LPAR1 is inhibited.
Discussion
A major finding of this study is that LPAR1 directly regulates
S1PR1 function. This constitutes a heretofore undescribed cross-
talk mechanism between LPA and S1P, two lysophospholipids
that acquired extracellular functions as vertebrates evolved
(Hla, 2005). As vertebrates acquired closed vascular systems,
immune cells, which are now faced with the challenge of navi-
gating in and out of the circulatory system, used S1P, an abun-
dant circulatory lipid mediator with defined spatial gradients for
lymphocyte trafficking (Cyster and Schwab, 2012). Our present
results suggest that LPA signaling modulates S1PR1 signaling in
specific contexts. The S1PR1 receptor is expressed abundantly in
endothelial cells, and its cell-surface expression is controlled by
multiple processes (Yanagida and Hla, 2017). For example, the
lymphocyte activation–inducedmolecule CD69 directly interacts
with S1PR1 to induce its ligand-dependent endocytosis, a process
that dictates whether lymphocytes egress (Shiow et al., 2006;
Bankovich et al., 2010). Indeed, tissue residency of various
T cells is controlled by CD69 (Shiow et al., 2006). In endothelial
cells, cell-surface signaling of S1PR1 regulates vascular barrier
function (Lee et al., 1999; Oo et al., 2007). However, S1PR2,
which activates the Rho GTPase, disrupts the endothelial barrier
(Sanchez et al., 2007), and its function in collecting LECs is
needed for lymphocyte trafficking from tissues to the lymph
nodes (Xiong et al., 2019). Thus, our finding that LPAR1 modu-
lates S1PR1 directly suggests functional cross-talk between LPA
and S1P.
Our study also provides a method to discover novel regu-
lators of GPCR signaling. By adapting a receptor reporter that
induces Venus expression downstream of GPCR/β-arrestin
coupling with a whole-genome–wide CRISPR/dCas9–dependent
transcriptional activation system, we identified LPAR1 as a
regulator of S1PR1 function. This system could be adapted to
other GPCRs or signaling pathways. Given the modularity and
flexibility of the CRISPR/dCas9 system, which can both activate
and repress genes (Shalem et al., 2015), we suggest that many
novel signaling proteins thatmodulate GPCRs could be identified
using similar screens.
We also describe, in detail, mechanistic insight into interac-
tions between S1PR1 and LPAR1. S1PR1 and LPAR1 interaction
requires the TM4 domain of S1PR1, which was previously
identified to be critical for direct interactionwith CD69, an event
critical for lymphocyte egress (Shiow et al., 2006). Activated
LPAR1 recruits β-arrestin, which is then transferred to S1PR1, a
phenomenon that we refer to as inter-GPCR β-arrestin coupling.
Recent structural studies indicate that both the C-terminal tail
and the third intracellular loop of GPCRs are involved in direct
interaction with β-arrestin (Ranjan et al., 2017). Since the
third intracellular loop of S1PR1 interacts directly with Gαi
family of heterotrimeric G proteins (Lee et al., 1996), inter-
GPCR β-arrestin signaling resulted in attenuation of S1PR1/
Gαi signaling. However, this mechanism, in and of itself, is not
sufficient to induce S1PR1 endocytosis. Thus, we suggest that
LPAR1-induced inter-GPCR β-arrestin coupling results in
suppression of signaling by plasma membrane–localized
S1PR1. This may allow rapid reversal of S1PR1 inhibitory ac-
tivity and thus acute regulation of S1PR1 GPCR.
Figure 5. LPAR1 inhibits S1PR1/G-protein signaling. (A) Flow cytometric
analysis showing surface Flag-S1PR1 expression after stimulation with 1 µM
S1P (blue line) or LPA (orange line) for 1 h or without simulation (gray) in
HEK293A cells stably expressing Flag-S1PR1 and LPAR1. (B) S1PR1 and LPAR1,
LPAR2, or LPAR5 were transfected with LgBiT-GNAO1, GNB1, and SmBiT-
GNGT1 plasmids. Luminescence was measured 6–9 min after AUY954 stim-
ulation. Data are derived from three to seven independent experiments and
are expressed as mean ± SD. P values were determined by two-way ANOVA
followed by Sidak’s multiple comparisons test comparing “S1PR1 + LPAR1” to
S1PR1 alone; *, P ≤ 0.01; **, P ≤ 0.0001. (C) Flow cytometric analysis of
HEK293A cells transfected with LPAR1 (orange), LPAR2 (brown line), or
LPAR3 (dark green line) tagged with Flag at the N-terminus or empty vector
(gray). RLU, relative light units.
Hisano et al. Journal of Experimental Medicine 1588
LPA/S1P cross-talk sculpts lymphatic junctions https://doi.org/10.1084/jem.20181895
D
ow
nloaded from
 https://rupress.org/jem
/article-pdf/216/7/1582/871095/jem
_20181895.pdf by Tohoku U
niversity user on 20 M
ay 2020
A key issue we addressed in this study is whether this
phenomenon occurs in vivo. For this, we turned to the re-
cently developed real-time S1PR1 luciferase signaling reporter
mice, which induce luciferase activity upon S1PR1/β-arrestin
coupling (Kono et al., 2017). Our data show that a constitutive
luciferase signal in several organs of adult S1PR1 luciferase
signaling reporter mice is LPAR1 dependent. In particular,
cervical and mesenteric lymph nodes showed strong lucifer-
ase activity that was suppressed by the LPAR1 antagonist
AM095. High-resolution confocal microscopy studies show
that sinus-lining LECs in cortical and medullary sinuses of
lymph nodes are the cells in which inter-GPCR β-arrestin
coupling between LPAR1 and S1PR1 occurs. Such structures
are the sites at which many lymphocytes egress from the
lymph node parenchyma into the lumen of the sinuses (Baluk
et al., 2007; Randolph et al., 2017). In addition, lymph from
afferent lymphatics that permeate through the lymph node
parenchyma flow through these sinus walls to ultimately
drain from the efferent lymphatic vessels. Our data suggest
that inter-GPCR β-arrestin coupling between LPAR1 and S1PR1
regulates the specialized properties of lymph node sinus-
lining LECs.
Figure 6. Endogenous LPAR1-induced inter-GPCR β-arrestin coupling in vivo. (A) MEFs isolated from S1PR1 luciferase signaling mice were added with
luciferin and then stimulated with LPA at various concentration in the presence or absence of 1 µM Ki16425. Luminescence was measured 8–12 min after LPA
stimulation. Data were derived from four independent experiments and are expressed as mean ± SD. P values were determined by two-way ANOVA followed
by Sidak’s multiple comparisons test comparing vehicle to Ki16425; *, P = 0.0104; **, P = 0.0021. (B) LPAR1 was transfected with S1PR1-SmBiT and LgBiT-
β-arrestin1. The cells were incubated with 1 µM AM095 for 30 min before stimulation, and luminescence was measured 15–20 min after LPA stimulation.
(C and D) Representative bioluminescence images of mice comparing the effects of vehicle (C) or AM095 (30 mg/kg; D) 2 h after gavage. Red open rectangles
were positioned around cephalic, thoracic, and epigastric regions. (E) The bioluminescence activity was quantified by determining the total flux (photons per
second [p/s]) in each region. n = 9 for each group; expressed as mean ± SD. P value was determined by paired t test. *, P ≤ 0.05; **, P ≤ 0.001. (F–H)Mice were
subjected to imaging before administration (F) and then dissected in order to image internal organs after vehicle (G) or AM095 (30 mg/kg; H) administration.
Arrow points to a lymph node. Lu, lung; Sp, spleen; βARR, β-arrestin; RLU, relative light units.
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It is noteworthy that S1P-dependent lymphocyte egress oc-
curs at cortical and medullary sinuses (Grigorova et al., 2009).
S1P that is enriched in lymph that is secreted from LECs via
SPNS2-dependent processes (Hisano et al., 2012; Mendoza et al.,
2012), together with low S1P in the lymphatic parenchymal
spaces, provides the spatial S1P gradient needed for efficient
lymphocyte egress (Cyster and Schwab, 2012). Cell-surface
S1PR1 on lymphocytes detects this gradient for a spatial cue
for the egress process, which involves traverse of the lympho-
cyte through the sinus-lining LECs (Pham et al., 2010). Once the
lymphocytes have entered the lumen of the cortical and med-
ullary sinuses, ensuing lymph flow helps drain them into ef-
ferent lymphatic vessels (Grigorova et al., 2009), thus ensuring
efficient lymphocyte trafficking. Our results suggest that LPAR1-
dependent inter-GPCR β-arrestin coupling keeps LEC S1PR1 in
an inactive state. It is noteworthy that LPA is generated in the
lymphoid tissue parenchyma (Nakasaki et al., 2008) and regu-
lates lymphocyte motility and traffic within the lymph node
(Zhang et al., 2012; Bai et al., 2013). That LPA and S1P treatment
induces additive effects on β-arrestin coupling to S1PR1 suggests
that these processes are independent and provide graded
responses.
We addressed the role of LPAR1-induced inter-GPCR
β-arrestin coupling in endothelial cell adherens junctions and
barrier function. Our results show that this mechanism alters the
junctional architecture and decreases endothelial barrier func-
tion. Specifically, junctions were remodeled from continuous
structures at cell–cell borders to punctate structures at the ter-
mini of actin-rich stress fibers. This results in the formation of
abundant intercellular gaps, which explains the decreased vas-
cular barrier function. Increased LPAR1-induced Rho GTPase
pathways and decreased S1PR1-induced Rac GTPase pathways
are likely involved, as determined by the analysis of the down-
stream targets p-MLC and F-actin at the cell cortex and stress
fibers, respectively (Knipe et al., 2015; Burg et al., 2018). These
results suggest that junctional remodeling may be a factor in the
high permeability and lymphocyte egress seen in sinus-lining
LECs of lymph nodes. Previous studies focused on junctions
have described the presence of button-like junctions in collecting
LECs of trachea lymphatics (Baluk et al., 2007), sinus-lining LECs
of lymph nodes (Pham et al., 2010), and lymphatic capillaries of
the small intestinal villi (Zhang et al., 2018). Such junctional
specialization was hypothesized to allow lymph fluid flow.
Whether such cell–cell junctions are important for efficient
lymphocyte egress is not known. Our data using LPAR1 inhibitor
(AM095) and the analysis of lymph nodes from Lpar1 KO mice is
consistent with the notion that LPAR1/S1PR1 cross-talk is im-
portant in LEC junctional specialization and provision of a
Figure 7. S1PR1/β-arrestin coupling in LPAR1 antagonist–treated lymph nodes. (A and B) Brachial lymph node sections from S1PR1-GFP signaling mice
treated with vehicle or AM095 were stained with B220 (red, B cells), CD8a (blue, T cells), and VEGFR3 (white, LECs; A); B220 (blue), CD11c (red, dendritic cells),
and LYVE1 (white, LECs); or CD169 (red, macrophages) and LYVE1 (white; B). LYVE1+ lymphatics were identified as subcapsular sinuses if they were found in
the subcapsular space and contained B cells and dendritic cells. Medullary sinuses contain CD169+ macrophages, and cortical sinuses are macrophage-free.
(C and D) Quantification of the total (C) and Prox1–double-positive (D) GFP signal (S1PR1-β-arrestin coupling) of brachial, inguinal, and mesenteric lymph
nodes of vehicle- or AM095-treated mice. Bars represent 200 µm in A and 20 µm in a, b, and B. Data were derived from eight sections for each group and are
expressed as mean ± SD. P value was determined using an unpaired t test with Welch’s correction comparing vehicle to AM095; **, P ≤ 0.0021; *, P ≤ 0.0332.
A.U., arbitrary unit.
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permissive environment for efficient lymphocyte egress. How-
ever, further studies using blocking antibodies to inhibit lym-
phocyte entry followed by detailed analysis of lymphocyte egress
kinetics in situations in which LEC LPAR1 activity is modified are
needed to unequivocally determine the relevance of this mech-
anism in lymphocyte trafficking.
In summary, we have described amechanism by which LPAR1
suppresses cell-surface S1PR1/Gαi signaling by inter-GPCR
β-arrestin coupling. This process regulates the LEC junctional
architecture and barrier function at sinus-lining endothelial cells
and may provide an optimal environment for efficient lympho-
cyte egress. Cross-talk between LPA and S1P receptors regulates
complex functions of circulatory and immune systems. Pharma-
cologicmodulation of this mechanismmay be useful in lymphatic
and immune disorders.
Materials and methods
Reagents
Primary antibodies used in this study include the following: PE
rat monoclonal anti-Flag tag (L5), Alexa Fluor 647 mouse mon-
oclonal anti-hemagglutinin (HA; 16B12), Alexa Fluor 647 rat
monoclonal CD8a (53–6.7), Alexa Fluor 647 rat monoclonal
CD169 (3D6.112), Alexa Fluor 594 rat monoclonal B220 (RA3-
6B2), Alexa Fluor 647 Armenian hamster monoclonal CD11c
(N418), rabbit polyclonal anti-Prox1, Brilliant violet 421 rat
monoclonal CD4 (GK1.5; BioLegend); rabbit polyclonal anti–
S1PR1 (H60), mouse monoclonal anti–VE-cadherin (F-8; Santa
Cruz Biotechnology); rabbit polyclonal anti–p-MLC2 (Cell Sig-
naling Technology); biotin-conjugated rat monoclonal anti-
LYVE1 (ALY7), allophycocyanin rat monoclonal CD8a (53–6.7;
eBioscience); goat polyclonal anti-VEGFR3, Goat polyclonal
anti–VE-cadherin (R&D Systems); rat monoclonal anti-PECAM-1
(MEC13.3; BD Pharmingen); and rabbit monoclonal anti-ERG
(EPR3864; Abcam). The secondary antibody used for Western
blotting was HRP-conjugated goat anti-rabbit IgG (Jackson Im-
munoResearch). The secondary antibodies used for immuno-
fluorescence were Alexa Fluor 405 donkey anti-goat IgG
(Abcam), Alexa Fluor 647 donkey anti-mouse and anti-goat IgG
(Invitrogen), Alexa Fluor 488 goat anti-rabbit IgG (Invitrogen),
DyLight 550 donkey anti-rat IgG (Invitrogen), and DyLight 405
donkey anti-rabbit IgG (Jackson ImmunoResearch). Alexa Fluor
405 streptavidin and Alexa Fluor 546 Phalloidin were from In-
vitrogen. S1P and LPA were from Avanti Polar Lipids. Ki16425
Figure 8. LPAR1 inhibits the formation of
continuous junctions in LECs. (A) Lymph node
sections (35 µm) from vehicle or 8-h AM095–
treated mice were stained with Prox1 (blue),
VE-cadherin (red), and PECAM-1 (green). Arrows
indicate VE-cadherin–positive adherens junc-
tions. Bars, 10 µm. (B) Quantification of junc-
tional length in the above confocal images.
Confocal images (n = 16) from three to five lymph
nodes from two mice for each group were ana-
lyzed as described, and junctions of various
lengths were quantified. Data are expressed as
mean ± SD. P values were determined using a
two-way ANOVA followed by Sidak’s multiple
comparisons test comparing vehicle to AM095;
**, P ≤ 0.0021; ****, P ≤ 0.0001.
Hisano et al. Journal of Experimental Medicine 1591
LPA/S1P cross-talk sculpts lymphatic junctions https://doi.org/10.1084/jem.20181895
D
ow
nloaded from
 https://rupress.org/jem
/article-pdf/216/7/1582/871095/jem
_20181895.pdf by Tohoku U
niversity user on 20 M
ay 2020
Figure 9. LPA/LPAR1 attenuates S1PR1-mediated barrier function. (A–D) HUVECs were analyzed for barrier function by real-time measurement of
transendothelial electrical resistance (TEER) in the absence (A and B) or presence (C and D) of doxycycline (Dox), which can induce LPAR1 expression by the
Tet-On system. 1 d after seeding, the cells were starved with 0.5% charcoal-treated FBS in the absence (A and C) or presence (B and D) of 1 µM Ki16425. At time
0, 100 nM AUY954 (blue), LPA (orange), AUY954 with LPA (dark green), or vehicle (black) was added. Data are from n = 3 independent experiments and
expressed as mean ± SD. P values were determined by two-way ANOVA followed by Sidak’s multiple comparisons test comparing “AUY954 + LPA” to AUY954
alone; *, P ≤ 0.0001. (E–H) HUVECs expressing LPAR1 were starved with 0.5% charcoal–treated FBS for 2 h and then treated with 100 nM AUY954 and/or LPA
for 30 min. Cells were fixed and stained for VE-cadherin (red) and p-MLC (green). F-actin and nuclei were stained with phalloidin (white) and DAPI (blue),
respectively. Arrowheads indicate intercellular gaps. Bars, 20 µm. (I) Quantification of VE-cadherin–positive area in above confocal images expressed as
mean ± SD. P value was determined by one-way ANOVA followed by Holm–Sidak’s multiple comparisons test; **, P ≤ 0.0021; *, P ≤ 0.0332. (J) Quantification
of junctional length in above confocal images expressed as mean ± SD. P value was determined by two-way ANOVA followed by Tukey’s multiple comparisons
test; ***, P ≤ 0.0002; **, P ≤ 0.0021; *, P < 0.0332. ns, not significant. AUY, AUY954.
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and AM095 were from Sigma. W146 was from Cayman. AUY954
was from Cellagen Technology. CSFE was purchased from Mo-
lecular Probes.
Cell culture
HEK293A, HEK293T, and MEF cells were cultured in DMEM
with L-glutamine, high glucose, and sodium pyruvate medium
(Corning) supplemented with 10% FBS and penicillin–
streptomycin (Corning) in a 37°C incubator with 5% CO2. U2OS
cells were cultured in McCoy’s 5A medium (Corning) supple-
mented with 10% FBS and 1% penicillin–streptomycin in a 37°C
incubator with 5% CO2. HUVECs were cultured in EGM-2 me-
dium (Lonza) supplemented with 10% FBS or M199 medium
(Corning) supplemented with 10% FBS, penicillin–streptomycin,
endothelial cell growth factor from sheep brain extract, and 5
U/ml heparin on human fibronectin–coated dishes in a 37°C
incubator with 5% CO2.
Generation of the U2OS cell line for library screening
The U2OS cells transduced with dCas9-VP64 (a gift from Feng
Zhang; 61425; Addgene) and MS2-P65-HSF (a gift from Feng
Zhang; 61426; Addgene; Konermann et al., 2015) were selected
with 6 µg/ml Blasticidin (Gibco) and 200 µg/ml Hygromycin
(Gibco), respectively. For the S1PR1-TANGO system, mouse
S1pr1 linked to the tetracycline transcriptional activator via a
TEV protease cleavage site and mouse β-arrestin2 linked to TEV
protease were designed to be cloned in a single vector using a
bicistronic internal ribosome entry site as described previously
(Shalem et al., 2015), and the PCR amplicon from this vector was
cloned into pCDH-CMV-MCS-EF1α-Neo lentivector (System Bio-
sciences) with NheI and NotI digestion sites. The nuclear local-
ization signal–Venus (a gift from Karel Svoboda; 15753; Addgene;
Petreanu et al., 2007) with PEST degradation sequence at
C-terminal was cloned into downstream of the tetracycline-
responsive element site on pLVX-TetOn lentivector (Clontech).
600 µg/ml Geneticin (G418; Gibco) and 1 µg/ml Puromycin
(Gibco) were used for selecting the cells transduced with these
constructs.
To produce lentiviral particles, HEK293T cells were seeded
on 10-cm dishes 1 d before transfection. On the following day,
when they had reached 80–90% confluency, medium was re-
placed by fresh 10% FBS/DMEMmedium 1 h before transfection.
20 µg lentiviral plasmid, 12.6 µg pMDL/pRRE, 9.6 µg pVSV-G,
and 6 µg pRSV-REV were diluted with water and mixed with
85.25 µl of 2 M CaCl2 solution, and then 688 µl of 2 × HBS so-
lution (274mMNaCl, 1.5mMNa2HPO4-7H2O, and 55mMHepes,
pH 7.0) was slowly added into the plasmid solution while vor-
texing. After incubation at room temperature for 20 min, the
solution mixture was added drop-wise directly to cells. Medium
was replaced by 10% FBS/McCoy’s 5A medium 12–16 h after
transfection. Lentiviral particle–containing supernatant was
harvested 2 d after the medium change and filtered with a 0.45-
µm syringe filter (Corning). PEG-it Virus Precipitation Solution
(System Biosciences) was used when concentration was needed.
U2OS cells were seeded 1 d before infection. On the following
day, when they had reached 20–30% confluency, medium was
replaced by 10% FBS/McCoy’s 5A medium containing lentiviral
particles. Medium was renewed 1 d after infection, and anti-
biotics were added the following day. The single clones were
isolated from antibiotic-resistant cells by limiting dilution and
then introduced with the SAM sgRNA library (a gift from Feng
Zhang; 1000000057; Addgene) at a lowmultiplicity of infection.
Library screening and sgRNA sequence analysis
The U2OS cells transduced with the SAM sgRNA library were
cultured in 400 µg/ml Zeocin (Gibco) to select cells harboring
SAM sgRNAs. Zeocin-resistant cells were allowed to grow
(presort cells) or starved with 0.5% charcoal-treated FBS for 2 d.
Then, starved cells were harvested, and Venus-positive cells
were sorted by FACS (post-sort cells) as shown in Fig. 1 A. The
sorted cells were seeded and expanded to repeat sorting. After a
second expansion, genomic DNAs were harvested from 10 × 107
pre- and post-sort cells using Quick-gDNA MidiPrep (Zymo
Research) according to the manufacturer’s protocol. Amplifica-
tion and purification of genomic DNAs for NGS analysis was
performed as described previously (Joung et al., 2017). After
quality control with Agilent 2200 TapeStation, libraries were
subjected to single-end sequencing on an Illumina NextSeq to
generate ≥50 million reads for both pre- and post-sort cells.
Reads were assigned to target genes using the previously
Figure 10. LPAR1 regulates transferred lymphocyte trafficking at lymph
nodes. (A) CFSE-labeled lymphocytes were injected into mice treated with
vehicle or AM095 (30 mg/kg, gavage), and then the number of CD4- and
CFSE-positive cells in lymph nodes and spleen was counted. n = 6 for each
group; expressed as mean ± SD. P values were determined using an unpaired
Student’s t test; *, P ≤ 0.0048. (B) 35-µm lymph node sections from vehicle-
or AM095-treated mice were stained with VEGFR3 (white, LECs), B220 (red,
B cells), CD8a (blue, T cells), and CFSE-CD4 (green, T cells). Bars, 100 µm. ns,
not significant.
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described Python script “count_spacers.py” with default pa-
rameters (Joung et al., 2017). The resultant count table was used
as input for the script “mageck” to generate significance scores
for each target gene (Li et al., 2014).
RNA isolation and quantitative real-time PCR
Total RNA was isolated using TRI reagent (Zymo Research) and
further purified with the Direct-zol RNA MicroPrep kit (Zymo
Research), treated with DNase (30 U/µg total RNA, QIAGEN),
and reverse transcribed using qScript XLT cDNA SuperMix
(Quanta Bioscience). Expression of mRNAwas quantitated using
PerfeCTa SYBR Green FastMix Reaction Mixes (Quanta Biosci-
ence) and the StepOnePlus Real-Time PCR System (Applied Bio-
systems) with cDNA equivalent to 7.5 ng total RNA.
Primers used for real-time PCR include the following (59–39):
HPRT-Fw, TGACACTGGCAAAACAATGCA; HPRT-Rv, GGTCCT
TTTCACCAGCAAGCT; SPNS2-Fw, AACGTGCTCAACTACCTG
GAC; SPNS2-Rv, ATGAACACTGACTGCAGCAG; LPAR1-Fw, ACT
GTGGTCATTGTGCTTGG; LPAR1-Rv, ACAGCACACGTCTAGAAG
TAAC; FAM156A-Fw, TATGCTGTTGGGAGGGAAGC; and
FAM156A-Rv, GCAGTATCGACATTCACATCGG.
NanoBiT assay
HEK293A cells were seeded at a density of 8 × 108 cells per 6-
cm dish 1 d before transfection. The following day, expression
vectors and polyethylenimine (PEI; pH 7.0; Polysciences, Inc.)
were diluted in 200 µl Opti-MEM (Gibco). 300 ng LgBiT-
β-arrestin1(EE) and 600 ng GPCR-SmBiT expression vectors
were used for the β-arrestin recruitment assay, and 200 ng
LgBiT-GNA, 1,000 ng GNB1, 1,000 ng SmBiT-GNGT1, and
400 ng GPCR expression vectors were used for the G-protein
dissociation assay. 10 µl of 1 mg/ml PEI was incubated in Opti-
MEM for 5 min at room temperature, and then diluted vectors
and PEI were combined andmixed by vortexing and incubated
for 20 min at room temperature. After incubation, the solu-
tion mixture was added drop-wise directly to cells. The fol-
lowing day, transfected cells were detached with 0.5 mM
EDTA/PBS. After centrifugation at 190 g for 5 min, cells were
suspended in 4 ml of 0.01% fatty acid–free BSA (Sigma)/HBSS
(Corning) supplemented with 5 mM Hepes (Corning) and
seeded on a white 96-well plate at 80 µl/well. 20 µl of 50 µM
coelenterazine (Cayman) was added and incubated for 2 h at
room temperature in the dark. Initial luminescence was
measured as baseline using SpectraMax L (Molecular De-
vices), and then cells were stimulated with ligands and incu-
bated at room temperature. Luminescence after stimulation
was measured and normalized with initial reads. Develop-
ment and validation of the NanoBiT G-protein dissociation
assay is described elsewhere (Inoue et al., 2019).
Split firefly luciferase complementation assay in MEFs
MEFs isolated from S1PR1 luciferase signaling mice (Kono et al.,
2017) were seed on a white 96-well plate. The following day,
medium was replaced by 80 µl of 0.01% fatty acid–free BSA/
HBSS supplemented with 5 mM Hepes and incubated for 2 h at
room temperature. 20 µl of 40 mg/ml Luciferin (Perkin Elmer)
was added, and initial luminescence was measured. After
stimulation with LPA, luminescence was measured and nor-
malized with initial reads. Bioluminescence in live mice and
internal organs was measured as described previously (Kono
et al., 2017).
Generation of Gα-depleted HEK293 cells using the CRISPR/
Cas9 system
Gα-depleted HEK293 cells were generated by mutating genes
encodingmembers of the Gαi family from previously established
HEK293 cells devoid of three Gα families (Gαs, Gαq, and Gα12;
Grundmann et al., 2018) using the CRISPR/Cas9 system as de-
scribed previously (Ran et al., 2013; O’Hayre et al., 2017), with
minor modifications. sgRNA constructs targeting the GNAI1,
GNAI2, GNAI3, GNAO1, GNAT1, GNAT2, and GNAZ genes, whose
mRNAwas expressed in HEK293 cells (Atwood et al., 2011), were
designed using a CRISPR design tool (http://crispr.mit.edu) so
that a SpCas9-mediated DNA cleavage site (3 bp upstream of the
protospacer adjacent motif [PAM] sequence [NGG]) encom-
passes a restriction enzyme–recognizing site. Designed sgRNA-
targeting sequences including the SpCas9 PAM sequences were
as follows: 59-CTTTGGTGACTCAGCCCGGGCGG-39 (GNAI1;
where the restriction enzyme site [Sma I in this case] is un-
derlined and the PAM sequence is in bold), 59-CGTAAAGACCAC
GGGGATCGTGG-39 (GNAI2; Mbo I), 59-AGCTTGCTT
CAGCAGATCCAGGG-39 (GNAI3; Mbo I), 59-AATCGCCTTGCT
CCGCTCGAGGG-39 (GNAO1; Xho I), 59-TTTCAGGTGCCGGTGAG
TCCGGG-39 (GNAT1; Hinf I), 59-AACCATGCCTCCTGAG
CTCGTGG-39 (GNAT2; Sac I), and 59-GATGCGGGTCAGCGAG
TCGATGG-39 (GNAZ; Hinf I). The designed sgRNA-targeting
sequences were inserted into the BbsI site of the pSpCas9(BB)-
2A-GFP (PX458) vector (a gift from Feng Zhang; 42230; Addg-
ene) using the following set of synthesized oligonucleotides: 59-
CACCGCTTTGGTGACTCAGCCCGGG-39 and 59-AAACCCCGG
GCTGAGTCACCAAAGC-39 (GNAI1; note that a guanine nucleo-
tide [G] was introduced at the −21 position of the sgRNA (un-
derlined), which enhances transcription of the sgRNA); 59-CAC
CGCGTAAAGACCACGGGGATCG-39 and 59-AAACCGATCCCC
GTGGTCTTTACGC-39 (GNAI2); 59-CACCGAGCTTGCTTCAGCAG
ATCCA-39 and 59-AAACTGGATCTGCTGAAGCAAGCTC-39 (GNAI3);
59-CACCGAATCGCCTTGCTCCGCTCGA-39 and 59-AAACTCGAG
CGGAGCAAGGCGATTC-39 (GNAO1); 59-CACCGTTTCAGGTGCCG
GTGAGTCC-39 and 59-AAACGGACTCACCGGCACCTGAAAC-39
(GNAT1); 59-CACCGAACCATGCCTCCTGAGCTCG-39 and 59-AAA
CCGAGCTCAGGAGGCATGGTTC-39 (GNAT2); 59-CACCGATGCGG
GTCAGCGAGTCGA-39 and 59-AAACTCGACTCGCTGACCCGCATC-
39 (GNAZ). Correctly inserted sgRNA-encoding sequences were
verified with a Sanger sequencing (Fasmac) using the primer 59-
ACTATCATATGCTTACCGTAAC-39.
To achieve successful selection of all-allele mutant clone, we
performed an iterative CRISPR/Cas9–mediated mutagenesis.
Specifically, in the first round, mutations were introduced in the
GNAZ gene. In the second round, the GNAI2, GNAI3, and GNAO1
genes were simultaneously mutated. In the last round, the
GNAI1, GNAT1, and GNAT2 genes were targeted. Briefly, HEK293
cells devoid of three Gα families (Grundmann et al., 2018) were
seeded into a 6-well culture plate and incubated for 1 d before
transfection. A plasmid encoding sgRNA and SpCas9-2A-GFP
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was transfected into the cells using Lipofectamine 2000 (Thermo
Fisher Scientific) according to the manufacturer’s protocol. 3 d
later, cells were harvested and processed for isolation of GFP-
positive cells (∼6% of cells) using a fluorescence-activated cell
sorter (SH800; Sony). After expansion of clonal cell colonies
with a limiting dilution method, clones were analyzed for mu-
tations in the targeted genes by restriction enzyme digestion as
described previously (O’Hayre et al., 2017; Grundmann et al.,
2018). PCR primers that amplify the sgRNA-targeting sites
were as follows: 59-AGCTGGTTATTCAGAAGAGGAGTG-39 and
59-TGGTCCTGATAGTTGACAAGCC-39 (GNAI1); 59-AAATGGCAT
GGGAGGGAAGG-39 and59-TAAAACCTCAGTGGGGCTGG-39 (GNAI2);
59-AGCTGGCAGTGCTGAAGAAG-39 and 59-TCATACAAATGA
CCAAGGGCTC-39 (GNAI3); 59-GGTCCTTACCGAGCAGGAG-39 and
59-CGACATTTTTGTTTCCAGCCC-39 (GNAO1); 59-TAGGTGTGG
CTACGGGGTC-39 and 59-GCACTCTTCCAGCGAGTACC-39 (GNAT1);
59-ACTGCTTCCATCTTAGGTCTTCG-39 and 59-CATCAACCCACC
CTCTCACC-39 (GNAT2); 59-CGAAATCAAGCTGCTCCTGC-39 and
59-TGTCCTCCAGGTGGTACTCG-39 (GNAZ). Candidate clones that
harbored restriction enzyme–resistant PCR fragments were
further assessed for their genomic DNA alterations by direct
sequencing or TA cloning as described previously (O’Hayre et al.,
2017; Grundmann et al., 2018).
Measurement of endothelial barrier function in vitro
Endothelial barrier function was evaluated by measuring the
resistance of a cell-covered electrode using an endothelial cell
impedance system Zθ device (Applied BioPhysics) in accordance
with the manufacturer’s instructions. Briefly, arrays were
cleaned with 10 mM L-cysteine, washed with sterile water,
coated with fibronectin for 30 min at 37°C, and incubated with
complete cell culture medium to run electrical stabilization.
HUVECs were seeded on a 96-well electrode array (96W10idf) at
a density of 2.5 × 104 cell per well in the presence or absence of
1 µg/ml doxycycline. The following day, confluent cells were
starved for 2–3 h in EBM-2 (Lonza) supplemented with 0.5%
charcoal–treated FBS and then stimulated with AUY954 and/or
LPA. Resistance was monitored and expressed as fractional re-
sistance, normalizing to the baseline at time 0.
Imaging studies in mice
All animal procedures were approved by the Animal Care and
Use Committees of the National Institute of Diabetes and Di-
gestive and Kidney Diseases, Boston Children’s Hospital, and
University of Maryland School of Medicine and performed in
accordance with National Institutes of Health guidelines. S1PR1-
GFP and S1PR1-luciferase signaling mice have been previously
described (Kono et al., 2014, 2017). Bioluminescence images
were acquired 2 h after injection with vehicle (10 µM Na2CO3
and 20% 2-hydroxypropyl-β-cyclodextrin) by gavage. 3 h after
the first imaging for vehicle, the AM095 (30 mg/kg) was ad-
ministrated to the mice through gavage, and bioluminescence
images were acquired 2 h later. S1PR1-GFP signaling mice were
treated with vehicle or AM095 (20mg/kg twice a day) for 5 d by
gavage, and lymph nodes were collected. C57BL/6J mice were
treated with AM095 (30 mg/kg twice by gavage, every 4 h), and
lymph nodes were collected 8 h after the first treatment. Lymph
nodes from Lpar1+/− and Lpar1−/− (Contos et al., 2000) were
harvested and sectioned for confocal microscopy imaging
studies.
Immunofluorescence staining
HUVECs were washed with cold PBS and fixed with 2% para-
formaldehyde (PFA) for 10 min at room temperature. U2OS cell
were washed with cold PBS and fixed with cold methanol for
10 min on ice. Lymph nodes were fixed in 4% PFA in PBS at 4°C,
washed in PBS and embedded in optimal cutting temperature
(OCT) compound (Tissue-Tek, Thermo Fisher Scientific) for
frozen section. Cryosections (35 µm) were permeabilized with
PBS-0.1% Triton at room temperature for 30 min and then
blocked with PBS containing 75 mMNaCl, 18 mMNa3 citrate, 2%
FBS, 1% BSA, and 0.05% Triton X-100. Incubation with primary
antibodies was performed overnight at 4°C, followed by three
washes with PBS and incubation with secondary antibodies for
3 h at room temperature. LEC images were obtained with cos-
taining of rat anti-CD31 antibody (BD Pharmigen), goat anti-VE-
cadherin, and rabbit anti-Prox1. Confocal images were taken
using a Zeiss LSM 800 with Airyscan confocal microscope. The
three- dimensional reconstructions of z-stack (xy projection)
images are shown. Image processing and quantification was
performed by using Adobe Photoshop, ImageJ, or Fiji software
(National Institutes of Health). GFP, CD31, VE-cadherin, and
Prox1-positive immunofluorescent signals were subjected to
threshold processing, and areas occupied by their signal were
quantified using Fiji software as described previously (Yanagida
et al., 2017). The junction lengths were measured using Fiji
software. Total lymph nodes from CFSE-CD4–injectedmice were
frozen in OCT, sectioned (35 µm), and stained with B220, CD8,
and VEGRF3 antibodies.
Immunoblot analysis
Cells were washed with cold PBS and lysed in modified RIPA
buffer (50 mM Tris, pH 7.4, 100 mM sodium chloride, 2 mM
EDTA, 1% Triton X-100, 0.5% Fos-Choline, and 10 mM sodium
azide) containing phosphatase inhibitors (1 mM sodium ortho-
vanadate, 1 mM sodium fluoride, and 5mM β-glycerophosphate)
and protease inhibitor cocktail (Sigma). After incubation on ice
for 30 min and a freeze/thaw cycle, protein concentrations in
supernatant from centrifugation at 10,000 g (15 min at 4°C)
were determined by bicinchoninic acid assay (Pierce) and de-
natured for 30 min at room temperature in Laemmli’s sample
buffer supplemented with 10% β-mercaptoethanol. An equal
amount of protein was loaded and separated on an SDS-
polyacrylamide gel and transferred electrophoretically to a
polyvinylidene difluoride membrane (Millipore). Transferred
proteins were then probed with rabbit polyclonal anti-S1PR1
(Santa Cruz Biotechnology) and HRP-conjugated goat anti-
rabbit IgG (Jackson ImmunoResearch).
Flow cytometry analysis
U2OS cells, HEK293A cells, and HUVECs were detached with
0.05% Trypsin (Corning), 0.5 mM EDTA, and Accutase (In-
novatice Cell Technologies), respectively. The harvested cells
were fixed with 1% PFA for 10 min on ice and labeled with PE
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anti-Flag and Alexa Fluor 647 anti-HA antibodies for detecting
cell–surface expression. The samples were analyzed using a BD
Calibur FACS system, and FlowJo software was used for data
analysis.
In vivo T cell migration assay
Mouse (C57BL/6; The Jackson Laboratory) CD4 T cells from
spleen and lymph nodes were prepared (CD4 enrichment kit;
STEMCELL Technologies) and CFSE labeled (Molecular Probes).
Recipient mice were given vehicle or 30 mg/kg AM095 by ga-
vage. 2 h later, 106 labeled CD4 T cells were adoptively trans-
ferred i.v. 16 h later, spleen or lymph nodes were collected and
stained with anti-CD4-BV421 (clone GK1.5; BioLegend) and
anti–CD8-APC (clone 53–6.7; eBioscience). The samples were
analyzed with FACSAria flow cytometer (BD Biosciences). Data
were analyzed with FlowJo software v 8.8.7 (Tree Star). Values
are expressed as the percentage of CSFE+ CD4+ cells out of total
CD4+ cells.
Spleen and lymph nodes were collected from above recip-
ient mice and immediately submerged in OCT compound
(Sakura Finetek). Tissues in OCT were quickly frozen using
dry ice and then kept at −80°C for long-term storage. Sections
of the lymph nodes were stained as above and imaged by
confocal microscopy.
Statistical analysis
Data are expressed as means ± SD. Statistical analysis was per-
formed as mentioned using Prism software (GraphPad). P values
<0.05 were considered statistically significant.
Online supplemental material
Fig. S1 shows how SPNS2 and LPAR1 SAM sgRNAs activate target
genes and Venus expression. Fig. S2 shows how LPAR1 stimula-
tion with LPA causes an additive effect in S1P-stimulated S1PR1-
SmBiT/β-arrestin coupling. Fig. S3 shows DNA sequences of the
Gα genomic loci in mutant HEK293 cells. Fig. S4 shows S1PR1
protein expression and localization. Fig. S5 shows how LPAR1-
mediated S1PR1/β-arrestin coupling regulates LEC junctions.
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